Clinical efficacy of distigmine bromide in the treatment of patients with underactive detrusor.

Article Details

Citation
Copy to clipboard

Bougas DA, Mitsogiannis IC, Mitropoulos DN, Kollaitis GC, Serafetinides EN, Giannopoulos AM

Clinical efficacy of distigmine bromide in the treatment of patients with underactive detrusor.

Int Urol Nephrol. 2004;36(4):507-12.

PubMed ID
15787326 [ View in PubMed
]
Abstract

PURPOSE: The aim of this study was to assess the clinical efficacy of distigmine bromide, an anticholinesterase agent, deemed to improve detrusor function thereby restoring normal voiding patterns in patients suffering from detrusor underactivity. MATERIALS AND METHODS: A total of 27 patients (11 men and 16 women) with poor detrusor function were included in the study. The diagnosis was established using pressure-flow studies. All patients received distigmine bromide at a dose of 5 mg three times daily for 4 weeks and re-attended for a follow-up urodynamic investigation. The results of baseline pressure-flow studies were compared to those after completion of treatment. RESULTS: Treatment with distigmine bromide resulted in a statistically significant reduction of residual volume and percent residual volume, obviating the need for intermittent self-catheterisation in 11 patients. In addition, maximum flow rate and detrusor pressure at maximum flow increased, although not significantly. The drug was generally well tolerated by the majority of patients. CONCLUSION: Distigmine bromide shows clinical efficacy in patients with poor detrusor function and may therefore be used alternatively in selected cases.

DrugBank Data that Cites this Article

Drugs